Compare Natural Alternatives International, Inc. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 6.24%
- The company has been able to generate a Return on Equity (avg) of 6.24% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Operating profit has grown by an annual rate -55.49% of over the last 5 years
3
The company has declared Negative results for the last 14 consecutive quarters
4
Risky - Negative EBITDA
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
USD 27 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
0.08
-14.75%
0.39
Revenue and Profits:
Net Sales:
37 Million
(Quarterly Results - Sep 2025)
Net Profit:
0 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
13.92%
0%
13.92%
6 Months
-14.79%
0%
-14.79%
1 Year
-25.06%
0%
-25.06%
2 Years
-49.18%
0%
-49.18%
3 Years
-65.33%
0%
-65.33%
4 Years
-76.26%
0%
-76.26%
5 Years
-78.34%
0%
-78.34%
Natural Alternatives International, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.40%
EBIT Growth (5y)
-55.49%
EBIT to Interest (avg)
3.73
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
0.03
Sales to Capital Employed (avg)
1.40
Tax Ratio
23.07%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
34.45%
ROCE (avg)
9.25%
ROE (avg)
6.24%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.42
EV to EBIT
-3.83
EV to EBITDA
-7.72
EV to Capital Employed
0.44
EV to Sales
0.28
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-11.49%
ROE (Latest)
-10.35%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 7 Schemes (12.69%)
Foreign Institutions
Held by 6 Foreign Institutions (0.68%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
37.30
33.70
10.68%
Operating Profit (PBDIT) excl Other Income
1.10
0.60
83.33%
Interest
0.20
0.20
Exceptional Items
-0.10
-1.50
93.33%
Consolidate Net Profit
-0.30
-7.20
95.83%
Operating Profit Margin (Excl OI)
-0.50%
-17.30%
1.68%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 10.68% vs 17.42% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 95.83% vs -227.27% in Jun 2025
Annual Results Snapshot (Consolidated) - Jun'25
Jun'25
Jun'24
Change(%)
Net Sales
129.60
113.80
13.88%
Operating Profit (PBDIT) excl Other Income
-2.60
-3.60
27.78%
Interest
0.90
0.40
125.00%
Exceptional Items
-1.80
-0.20
-800.00%
Consolidate Net Profit
-13.60
-7.20
-88.89%
Operating Profit Margin (Excl OI)
-55.10%
-72.70%
1.76%
USD in Million.
Net Sales
YoY Growth in year ended Jun 2025 is 13.88% vs -27.52% in Jun 2024
Consolidated Net Profit
YoY Growth in year ended Jun 2025 is -88.89% vs -388.00% in Jun 2024
About Natural Alternatives International, Inc. 
Natural Alternatives International, Inc.
Pharmaceuticals & Biotechnology
Natural Alternatives International, Inc. is a formulator, manufacturer and marketer of nutritional supplements. The Company operates through three segments: private-label contract manufacturing, patent and trademark licensing, and branded products. The private-label contract manufacturing segment primarily relates to the provision of private-label contract manufacturing services to companies that market and distribute nutritional supplements and other healthcare products. The patent and trademark licensing segment primarily includes direct raw material sales and royalty income from its license and supply agreements associated with the sale and use of beta-alanine under its CarnosSyn trade name. The branded products segment relates to the marketing and distribution of branded nutritional supplements and consists primarily of the products sold under its Pathway to Healing product line.
Company Coordinates 
Company Details
1535 Faraday Ave , CARLSBAD CA : 92008-7319
Registrar Details






